Immunoprecise Stock Financials

IPA -  USA Stock  

USD 5.30  0.15  2.75%

Understanding current and past Immunoprecise Antibodies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Immunoprecise Antibodies' financial statements are interrelated, with each one affecting the others. For example, an increase in Immunoprecise Antibodies' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Immunoprecise Antibodies' financials over time to get the whole picture.
Immunoprecise Antibodies Tangible Asset Value is projected to increase significantly based on the last few years of reporting. The past year's Tangible Asset Value was at 61.09 Million. The current year Working Capital is expected to grow to about 53.1 M, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are forecasted to decline to (1.8 M).
Please harness analysis of Immunoprecise Antibodies fundamentals to determine if markets are correctly pricing the company. We were able to interpolate data for twenty-nine available reported financial drivers for Immunoprecise Antibodies, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Immunoprecise Antibodies financials, including its number of shares shorted, net income, book value per share, as well as the relationship between the revenue and total debt . Given that Immunoprecise Antibodies has a shares owned by institutions of 7.40 %, we strongly advise you to confirm Immunoprecise Antibodies regular market performance to make sure the company can sustain itself down the road. Use Immunoprecise Antibodies to protect your portfolios against small market fluctuations. The stock experiences an unexpected downward movement. The market is reacting to new fundamentals. Check odds of Immunoprecise Antibodies to be traded at $5.09 in 90 days.
  
Refresh
With this module, you can analyze Immunoprecise financials for your investing period. You should be able to track the changes in Immunoprecise Antibodies individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Immunoprecise Antibodies is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Immunoprecise Antibodies includes many different criteria found on its balance sheet. For example, investors should never minimize Immunoprecise Antibodies' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Immunoprecise Antibodies' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Immunoprecise Antibodies.

Immunoprecise Antibodies Cash

Chance Of Financial Distress
Less than 28
Immunoprecise Antibodies has less than 28 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Immunoprecise Antibodies stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Immunoprecise Antibodies' official financial statements usually reflect Immunoprecise Antibodies' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Immunoprecise Antibodies. For example, before you start analyzing numbers published by Immunoprecise accountants, it's critical to develop an understanding of what Immunoprecise Antibodies' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Immunoprecise Antibodies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunoprecise Antibodies' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Immunoprecise Antibodies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunoprecise Antibodies. Please utilize our Beneish M Score to check the likelihood of Immunoprecise Antibodies' management to manipulate its earnings.

Immunoprecise Antibodies Company Summary

Immunoprecise Antibodies competes with Berkeley Lights, and Brickell Biotech. ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing B cell sorting, screening, and sequencing custom, immune, and naive phage display production and screening transgenic animals and multi-species antibody discovery bi-specific, tri-specific, VHH, and VNAR antibody manufacturing DNA cloning, protein and antibody downstream processing antibody characterization on label-free biosensors and antibody engineering transient and stable cell line generation antibody optimization and humanization hybridoma production with multiplexed, high-throughput screening, and clone-picking and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Foreign Associate  Exotistan
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP45257F101
Older SymbolIPATF
LocationBritish Columbia; Canada
Business Address32044464 Markham Street
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.immunoprecise.com
Phone250 483 0308
Related EntityIPA
CurrencyUSD - US Dollar
You should never invest in Immunoprecise Antibodies without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Immunoprecise Stock, because this is throwing your money away. Analyzing the key information contained in Immunoprecise Antibodies' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Immunoprecise Antibodies Key Financial Ratios

Generally speaking, Immunoprecise Antibodies' financial ratios allow both analysts and investors to convert raw data from Immunoprecise Antibodies' financial statements into concise, actionable information that can be used to evaluate the performance of Immunoprecise Antibodies over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Immunoprecise Antibodies reports annually and quarterly.

Immunoprecise Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Immunoprecise Antibodies's current stock value. Our valuation model uses many indicators to compare Immunoprecise Antibodies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunoprecise Antibodies competition to find correlations between indicators driving Immunoprecise Antibodies's intrinsic value. More Info.
Immunoprecise Antibodies is currently regarded as number one stock in cash flow from operations category among related companies. It is currently regarded as number one stock in net income category among related companies . Immunoprecise Antibodies Net Income is projected to decrease significantly based on the last few years of reporting. The past year's Net Income was at (8.44 Million). Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunoprecise Antibodies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunoprecise Antibodies' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunoprecise Antibodies' earnings, one of the primary drivers of an investment's value.

Immunoprecise Antibodies Systematic Risk

Immunoprecise Antibodies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Immunoprecise Antibodies volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Immunoprecise Antibodies correlated with the market. If Beta is less than 0 Immunoprecise Antibodies generally moves in the opposite direction as compared to the market. If Immunoprecise Antibodies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Immunoprecise Antibodies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Immunoprecise Antibodies is generally in the same direction as the market. If Beta > 1 Immunoprecise Antibodies moves generally in the same direction as, but more than the movement of the benchmark.
.

About Immunoprecise Antibodies Financials

What exactly are Immunoprecise Antibodies Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Immunoprecise Antibodies' income statement, its balance sheet, and the statement of cash flows. Potential Immunoprecise Antibodies investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Immunoprecise Antibodies investors may use each financial statement separately, they are all related. The changes in Immunoprecise Antibodies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunoprecise Antibodies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Immunoprecise Antibodies is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Immunoprecise grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Immunoprecise Antibodies Thematic Clasifications

Immunoprecise Antibodies is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Pharmaceutical Products Idea
Pharmaceutical ProductsView
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas

Immunoprecise Antibodies May 28, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Immunoprecise Antibodies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Immunoprecise Antibodies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Immunoprecise Antibodies based on widely used predictive technical indicators. In general, we focus on analyzing Immunoprecise Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Immunoprecise Antibodies's daily price indicators and compare them against related drivers.
Downside Deviation4.13
Information Ratio0.0488
Maximum Drawdown22.0
Value At Risk(7.11)
Potential Upside8.54
Please see Risk vs Return Analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.